
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Experimental Therapeutics, Preclinical Pharmacology |
1 Cancer Biomarkers and Prevention Group, Departments of Biochemistry and Cancer Studies and Molecular Medicine, University of Leicester, Leicester, United Kingdom, and 2 National Institute on Aging, Gerontology Research Center, Baltimore, Maryland
Indole-3-carbinol (I3C) and 3,3'-diindolylmethane (DIM) are promising cancer chemopreventive agents in rodent models, but there is a paucity of data on their pharmacokinetics and tissue disposition. The disposition of I3C and its acid condensation products, DIM, [2-(indol-3-ylmethyl)-indol-3-yl]indol-3-ylmethane (LTr1), indolo[3,2b]carbazole (ICZ) and 1-(3-hydroxymethyl)-indolyl-3-indolylmethane (HI-IM) was studied, after oral administration of I3C (250 mg/kg) to female CD-1 mice. Blood, liver, kidney, lung, heart, and brain were collected between 0.25 and 24 h after administration and the plasma and tissue concentrations of I3C and its derivatives determined by high-performance liquid chromotography. I3C was rapidly absorbed, distributed, and eliminated from plasma and tissues, falling below the limit of detection by 1 h. Highest concentrations of I3C were detected in the liver where levels were approximately 6-fold higher than those in the plasma. Levels of DIM, LTr1, and HI-IM were much lower, although they persisted in plasma and tissues for considerably longer. DIM and HI-IM were still present in the liver 24 h after I3C administration. Tissue levels of DIM and LTr1 were found to be in equilibrium with plasma at almost every time point measured. In addition to acid condensation products of I3C, a major oxidative metabolite (indole-3-carboxylic acid) and a minor oxidative metabolite (indole-3-carboxaldehyde) were detected in plasma of mice after oral administration of I3C. ICZ was also tentatively identified in the liver of these mice. This study shows for the first time that, after oral administration to mice, I3C, in addition to its acid condensation products, is absorbed from the gut and distributed systemically into a number of well-perfused tissues, thus allowing the possibility for some pharmacological activity of the parent compound in vivo.
This article has been cited by other articles:
![]() |
S. Smith, D. Sepkovic, H. L. Bradlow, and K. J. Auborn 3,3'-Diindolylmethane and Genistein Decrease the Adverse Effects of Estrogen in LNCaP and PC-3 Prostate Cancer Cells J. Nutr., December 1, 2008; 138(12): 2379 - 2385. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. A. Reed, J. M. Sunega, D. K. Sullivan, J. C. Gray, M. S. Mayo, J. A. Crowell, and A. Hurwitz Single-Dose Pharmacokinetics and Tolerability of Absorption-Enhanced 3,3'-Diindolylmethane in Healthy Subjects Cancer Epidemiol. Biomarkers Prev., October 1, 2008; 17(10): 2619 - 2624. [Abstract] [Full Text] [PDF] |
||||
![]() |
F.-M. Lin, L.-R. Chen, E.-H. Lin, F.-C. Ke, H.-Y. Chen, M.-J. Tsai, and P.-W. Hsiao Compounds from Wedelia chinensis synergistically suppress androgen activity and growth in prostate cancer cells Carcinogenesis, December 1, 2007; 28(12): 2521 - 2529. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. W. Rahman, S. Ali, A. Aboukameel, S. H. Sarkar, Z. Wang, P. A. Philip, W. A. Sakr, and A. Raz Inactivation of NF-{kappa}B by 3,3'-diindolylmethane contributes to increased apoptosis induced by chemotherapeutic agent in breast cancer cells Mol. Cancer Ther., October 1, 2007; 6(10): 2757 - 2765. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. C. Tilton, J. D. Hendricks, G. A. Orner, C. B. Pereira, G. S. Bailey, and D. E. Williams Gene expression analysis during tumor enhancement by the dietary phytochemical, 3,3'-diindolylmethane, in rainbow trout Carcinogenesis, July 1, 2007; 28(7): 1589 - 1598. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. A. Reed, D. W. Arneson, W. C. Putnam, H. J. Smith, J. C. Gray, D. K. Sullivan, M. S. Mayo, J. A. Crowell, and A. Hurwitz Single-Dose and Multiple-Dose Administration of Indole-3-Carbinol to Women: Pharmacokinetics Based on 3,3'-Diindolylmethane Cancer Epidemiol. Biomarkers Prev., December 1, 2006; 15(12): 2477 - 2481. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. L. Petersen, S. Krishnan, and E. D. Hudgens The Aryl Hydrocarbon Receptor Pathway and Sexual Differentiation of Neuroendocrine Functions Endocrinology, June 1, 2006; 147(6): s33 - s42. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. C. Tilton, S. A. Givan, C. B. Pereira, G. S. Bailey, and D. E. Williams Toxicogenomic Profiling of the Hepatic Tumor Promoters Indole-3-Carbinol, 17{beta}-Estradiol and {beta}-Naphthoflavone in Rainbow Trout Toxicol. Sci., March 1, 2006; 90(1): 61 - 72. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. A. Savino III, J. F. Evans, D. Rabinowitz, K. J. Auborn, and T. H. Carter Multiple, disparate roles for calcium signaling in apoptosis of human prostate and cervical cancer cells exposed to diindolylmethane. Mol. Cancer Ther., March 1, 2006; 5(3): 556 - 563. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |